Immuneering Corp (IMRX) — Cash Flow-to-Debt Ratio
Latest as of September 2025:
-0.92x
Immuneering Corp (IMRX) has a Cash Flow-to-Debt Ratio of -0.92x as of September 2025, meaning its operating cash flow of $-11.98 Million could theoretically repay -1% of its total liabilities ($13.08 Million) in one year. See IMRX free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.92x
Operating CF / Total Liabilities
Operating Cash Flow
$-11.98 Million
USD
Total Liabilities
$13.08 Million
USD
Data as of
Sep 2025
Most recent filing
Immuneering Corp Cash Flow-to-Debt Ratio (2019–2024)
Historical debt coverage capacity for Immuneering Corp across 6 annual periods. For the full cash flow conversion analysis, see Immuneering Corp operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for Immuneering Corp (2019–2024)
Year-by-year debt coverage analysis for Immuneering Corp.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -4.86x | $-55.00 Million | $11.33 Million | ▼ -19.1% |
| 2023 | -4.08x | $-48.97 Million | $12.01 Million | ▼ -15.7% |
| 2022 | -3.52x | $-44.10 Million | $12.52 Million | ▼ -22.5% |
| 2021 | -2.88x | $-30.85 Million | $10.72 Million | ▼ -1098.3% |
| 2020 | -0.24x | $-14.62 Million | $60.90 Million | ▼ -11.5% |
| 2019 | -0.22x | $-4.44 Million | $20.63 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.